These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 18183537)
21. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. Serajee FJ; Huq AM Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053 [TBL] [Abstract][Full Text] [Related]
22. A New SV2A Ligand for Epilepsy. Rogawski MA Cell; 2016 Oct; 167(3):587. PubMed ID: 27768878 [TBL] [Abstract][Full Text] [Related]
23. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. Kenda BM; Matagne AC; Talaga PE; Pasau PM; Differding E; Lallemand BI; Frycia AM; Moureau FG; Klitgaard HV; Gillard MR; Fuks B; Michel P J Med Chem; 2004 Jan; 47(3):530-49. PubMed ID: 14736235 [TBL] [Abstract][Full Text] [Related]
24. Structure activity relationships of novel antiepileptic drugs. Mittapalli GK; Roberts E Curr Med Chem; 2014; 21(6):722-54. PubMed ID: 24251563 [TBL] [Abstract][Full Text] [Related]
25. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. Danish A; Namasivayam V; Schiedel AC; Müller CE Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28220535 [TBL] [Abstract][Full Text] [Related]
26. The pipeline for antiepileptic drugs. McKelvy JF Epilepsy Res Suppl; 1993; 10():3-8. PubMed ID: 8251104 [No Abstract] [Full Text] [Related]
27. Clinical and laboratory investigations in various types of epilepsy during Morfolep administration. Lehoczky T Ther Hung; 1968; 16(3):117-20. PubMed ID: 5726083 [No Abstract] [Full Text] [Related]
28. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Chazot PL Curr Opin Investig Drugs; 2007 Jul; 8(7):570-9. PubMed ID: 17659477 [TBL] [Abstract][Full Text] [Related]
29. [Results of Suxilep therapy in epileptic seizures in childhood]. Todt H; Munde B; Wünsche W Dtsch Gesundheitsw; 1971 Nov; 26(46):2187-90. PubMed ID: 5148801 [No Abstract] [Full Text] [Related]
30. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro. Martella G; Bonsi P; Sciamanna G; Platania P; Madeo G; Tassone A; Cuomo D; Pisani A Epilepsia; 2009 Apr; 50(4):702-10. PubMed ID: 19055493 [TBL] [Abstract][Full Text] [Related]
31. Angels and demons: neurotrophic factors and epilepsy. Simonato M; Tongiorgi E; Kokaia M Trends Pharmacol Sci; 2006 Dec; 27(12):631-8. PubMed ID: 17055067 [TBL] [Abstract][Full Text] [Related]
33. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. Brochot A; Zamacona M; Stockis A Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):256-62. PubMed ID: 20102365 [TBL] [Abstract][Full Text] [Related]
35. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Kaminski RM; Matagne A; Patsalos PN; Klitgaard H Epilepsia; 2009 Mar; 50(3):387-97. PubMed ID: 18627416 [TBL] [Abstract][Full Text] [Related]
36. Tritium-labeled brivaracetam with high specific activity: preparation, characterization and application in human brain samples. Hildenbrand S; Schoch S; von Lehe M; Surges R; Müller CE ChemMedChem; 2012 Aug; 7(8):1369-74. PubMed ID: 22740425 [No Abstract] [Full Text] [Related]
38. [Synthesis and activity of substituted 5-aryl-2-pyrrolidinones(DL)]. Bocchi V; Gardini GP; Pinza M Farmaco Sci; 1971 May; 26(5):429-34. PubMed ID: 5561446 [No Abstract] [Full Text] [Related]
39. Brivaracetam (Briviact) for epilepsy. Med Lett Drugs Ther; 2016 Jul; 58(1499):95-6. PubMed ID: 27403785 [No Abstract] [Full Text] [Related]
40. [The treatment of epilepsy with special reference to petit mal]. Landolt H Helv Med Acta; 1963 Nov; 30(4):347-52. PubMed ID: 4964152 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]